China Immunosuppressant Drugs Market Size & Outlook
Related Markets
China immunosuppressant drugs market highlights
- The China immunosuppressant drugs market generated a revenue of USD 5,158.6 million in 2020 and is expected to reach USD 9,785.3 million by 2027.
- The China market is expected to grow at a CAGR of 9.6% from 2021 to 2027.
- In terms of segment, monoclonal antibodies was the largest revenue generating drug class in 2020.
- Monoclonal Antibodies is the most lucrative drug class segment registering the fastest growth during the forecast period.
Immunosuppressant drugs market data book summary
| Market revenue in 2020 | USD 5,158.6 million |
| Market revenue in 2027 | USD 9,785.3 million |
| Growth rate | 9.6% (CAGR from 2020 to 2027) |
| Largest segment | Monoclonal antibodies |
| Fastest growing segment | Monoclonal Antibodies |
| Historical data | 2016 - 2019 |
| Base year | 2020 |
| Forecast period | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Calcineurin Inhibitors, MTOR Inhibitors, Antiproliferative Agents, Monoclonal Antibodies |
Other key industry trends
- In terms of revenue, China accounted for 5.4% of the global immunosuppressant drugs market in 2020.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2027.
- In Asia Pacific, China immunosuppressant drugs market is projected to lead the regional market in terms of revenue in 2027.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 9,785.3 million by 2027.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Immunosuppressant Drugs Market Scope
Immunosuppressant Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| No records found. | ||||
China immunosuppressant drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunosuppressant drugs market will help companies and investors design strategic landscapes.
Monoclonal antibodies was the largest segment with a revenue share of 73.48% in 2020. Horizon Databook has segmented the China immunosuppressant drugs market based on calcineurin inhibitors, mtor inhibitors, antiproliferative agents, monoclonal antibodies covering the revenue growth of each sub-segment from 2016 to 2027.
China is considered one of the favorable emerging markets around the world, mainly because of its large population base, low cost of manufacturing and strong R&D in the country. China’s population is ageing and, like many countries, the major disease burden is chronic illnesses. Chinese contemporary culture greatly values the importance of physical appearance of women and lays strong emphasis on ideal beauty standards.
Therefore, the country has become a hub for cosmetic dentistry procedures, and the major factor driving this market is increasing workplace competition. According to recently released data obtained from the 4th National Oral Health Epidemiology Survey, dental caries and periodontal disease are still major diseases that affect the oral health of Chinese people.
The prevalence of caries was above 50% in all age groups. Moreover dental tourism has increased in China, as Americans travel to the country for treatment because of availability of advanced technology, high quality of services, and shorter waiting period for most procedures, as well as ample availability of trained personnel. According to Ipsos, about 33 % people from China reported that they visited or consulted with a dentist or dental surgeon once a year and 18% visited twice a year.
Reasons to subscribe to China immunosuppressant drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of China immunosuppressant drugs market databook
-
Our clientele includes a mix of immunosuppressant drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the China immunosuppressant drugs market, including forecasts for subscribers. This country databook contains high-level insights into China immunosuppressant drugs market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
China immunosuppressant drugs market size, by drug class, 2016-2027 (US$M)
China Immunosuppressant Drugs Market Share, 2020 & 2027 (US$M)
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
